01/2021 - Cancer research needs a better map
It is time to move beyond tumour sequencing data to identify vulnerabilities in cancers.
01/2021 - Minimal genome-wide human CRISPR-Cas9 library
CRISPR guide RNA libraries have been iteratively improved to provide increasingly efficient reagents, although their large size is a barrier for many applications. We design an optimised minimal genome-wide human CRISPR-Cas9 library (MinLibCas9) by mining existing large-scale gene loss-of-function datasets, resulting in a greater than 42% reduction in size compared to other CRISPR-Cas9 libraries while […]
01/2021 - Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses
Background Polygenic risk scores (PRSs) can stratify populations into cardiovascular disease (CVD) risk groups. We aimed to quantify the potential advantage of adding information on PRSs to conventional risk factors in the primary prevention of CVD. Methods and findings Using data from UK Biobank on 306,654 individuals without a history of CVD and not on […]
01/2021 - Redefining false discoveries in cancer data analyses
The nature of biological networks still brings challenges related to computational complexity, interpretable results and statistical signifcance. Recent work proposes a new method that paves the way for addressing these issues when analyzing cancer genomic data.
01/2021 - A commercial antibody to the human condensin II subunit NCAPH2 cross-reacts with a SWI/SNF complex component
Condensin complexes compact and disentangle chromosomes in preparation for cell division. Commercially available antibodies raised against condensin subunits have been widely used to characterise their cellular interactome. Here we have assessed the specificity of a polyclonal antibody (Bethyl A302-276A) that is commonly used as a probe for NCAPH2, the kleisin subunit of condensin II, in […]
Pagina precedente